Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?
Chimeric antigen receptor (CAR) T cell therapy has emerged as a revolutionary treatment option for highly aggressive B cell malignancies. Clinical trials of CD19 CAR T cells for the management of relapsed and/or refractory non-Hodgkin lymphoma (NHL) have shown markedly improved survival and response...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Innovative Healthcare Institute
2021-08-01
|
| Series: | Journal of Immunotherapy and Precision Oncology |
| Subjects: | |
| Online Access: | https://jipo.org/doi/pdf/10.36401/JIPO-21-2 |
| _version_ | 1828072848148660224 |
|---|---|
| author | Kevin Tang Loretta J. Nastoupil |
| author_facet | Kevin Tang Loretta J. Nastoupil |
| author_sort | Kevin Tang |
| collection | DOAJ |
| description | Chimeric antigen receptor (CAR) T cell therapy has emerged as a revolutionary treatment option for highly aggressive B cell malignancies. Clinical trials of CD19 CAR T cells for the management of relapsed and/or refractory non-Hodgkin lymphoma (NHL) have shown markedly improved survival and response rates. The goal of this review is to evaluate whether the results from these clinical trials are reflective of real-world practices through the analysis of published literature of the commercially available CAR T cell products. We have found that despite the significantly different patient characteristics, the adverse events and response rates of real-world patients were similar to those of the clinical trials. Of interest, several groups excluded from the clinical trials, such as patients with HIV infection, chronic viral hepatitis, and secondary CNS (central nervous system) lymphoma, had case reports of promising outcomes. |
| first_indexed | 2024-04-11T01:18:31Z |
| format | Article |
| id | doaj.art-75083ea9e54a4f548f1dffb1fe4fafd3 |
| institution | Directory Open Access Journal |
| issn | 2666-2345 2590-017X |
| language | English |
| last_indexed | 2024-04-11T01:18:31Z |
| publishDate | 2021-08-01 |
| publisher | Innovative Healthcare Institute |
| record_format | Article |
| series | Journal of Immunotherapy and Precision Oncology |
| spelling | doaj.art-75083ea9e54a4f548f1dffb1fe4fafd32023-01-03T16:42:10ZengInnovative Healthcare InstituteJournal of Immunotherapy and Precision Oncology2666-23452590-017X2021-08-0115015910.36401/JIPO-21-2i2590-017X-4-3-150Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?Kevin Tang0Loretta J. Nastoupil11 Department of Medicine, Baylor College of Medicine, Houston, TX, USA2 Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USAChimeric antigen receptor (CAR) T cell therapy has emerged as a revolutionary treatment option for highly aggressive B cell malignancies. Clinical trials of CD19 CAR T cells for the management of relapsed and/or refractory non-Hodgkin lymphoma (NHL) have shown markedly improved survival and response rates. The goal of this review is to evaluate whether the results from these clinical trials are reflective of real-world practices through the analysis of published literature of the commercially available CAR T cell products. We have found that despite the significantly different patient characteristics, the adverse events and response rates of real-world patients were similar to those of the clinical trials. Of interest, several groups excluded from the clinical trials, such as patients with HIV infection, chronic viral hepatitis, and secondary CNS (central nervous system) lymphoma, had case reports of promising outcomes.https://jipo.org/doi/pdf/10.36401/JIPO-21-2lymphomanon-hodgkin lymphomacellular therapychimeric antigen receptorcar t cell therapy |
| spellingShingle | Kevin Tang Loretta J. Nastoupil Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies? Journal of Immunotherapy and Precision Oncology lymphoma non-hodgkin lymphoma cellular therapy chimeric antigen receptor car t cell therapy |
| title | Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies? |
| title_full | Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies? |
| title_fullStr | Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies? |
| title_full_unstemmed | Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies? |
| title_short | Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies? |
| title_sort | real world experiences of car t cell therapy for large b cell lymphoma how similar are they to the prospective studies |
| topic | lymphoma non-hodgkin lymphoma cellular therapy chimeric antigen receptor car t cell therapy |
| url | https://jipo.org/doi/pdf/10.36401/JIPO-21-2 |
| work_keys_str_mv | AT kevintang realworldexperiencesofcartcelltherapyforlargebcelllymphomahowsimilararetheytotheprospectivestudies AT lorettajnastoupil realworldexperiencesofcartcelltherapyforlargebcelllymphomahowsimilararetheytotheprospectivestudies |